Cardiomyopathy Trial, Recruiting NCT05818605 Sponsor: University of California, San Francisco Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT05818605
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 80 years old who have been diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle is thicker than normal), confirmed by a specific heart ultrasound measurement or by other supporting signs such as a family history of the condition or a positive genetic test.
  • People whose heart's main outflow passage does not show significant blockage, both at rest and during physical activity (as measured during testing).
  • People whose heart is pumping at least 50% of its blood volume with each beat, as measured by a specific ultrasound method.
  • People who have access to exercise equipment, either at home or at a gym or fitness centre.
  • People who are able to complete online surveys and use a smartphone as part of the study requirements.
  • People who are able to participate in 24 weeks of exercise training.

Who may not be able to join:

  • People who have a history of fainting or dangerous heart rhythm problems triggered by exercise.
  • People who are currently being assessed for a procedure to reduce blockage in the heart's outflow passage, or who are fewer than 3 months past such an assessment.
  • People who have previously had a surgical or catheter-based procedure to reduce thickening of the heart wall.
  • People who have had a heart device (implantable defibrillator) placed within the past 3 months.
  • People who have shown a significant drop in blood pressure during exercise testing (a drop of more than 20 mmHg from their starting blood pressure).
  • People who have had a serious worsening of their heart condition in the past 3 months, including severe heart failure symptoms or severe chest pain symptoms at rest or with minimal activity.
  • People whose heart is pumping less than 50% of its blood volume with each beat, as measured by heart ultrasound.
  • People whose life expectancy is less than 12 months.
  • People who are pregnant or planning to become pregnant.
  • People who are unable to exercise due to any medical or other reason.
  • People who are unwilling to avoid competitive sports, sudden bursts of intense activity, or heavy resistance-type exercise for the duration of the study, if assigned to the non-exercise group.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Theodore P Abraham, M.D, University of California, San Francisco

Phone: 415-514-1125

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 February 2023
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in V O2 max; Change in peak VO2 %

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov